Metraipolis › archive › dc_d84bd2a2adf7

Repurposing Masitinib Mesylate as a Novel FOXM1 Inhibitor for the Treatment of Aggressive Solid Tumors: Preclinical Validation in Human Breast and Oral Cancer… — Europe PMC PMID:42518399

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42518399
DOI
10.1021/acsomega.6c02787
License (as archived)
solo-consultazione
Archived
2026-10-31T07:12:27.719Z
SHA-256 of the archived text
f890f11f1e7c9802c21db2e503ecd1431be0c608dc9b38ff4963368c493c6f06
Stable URL of this page
https://metraipolis.com/documento/dc_d84bd2a2adf7

How to cite

Repurposing Masitinib Mesylate as a Novel FOXM1 Inhibitor for the Treatment of Aggressive Solid Tumors: Preclinical Validation in Human Breast and Oral Cancer… — Europe PMC PMID:42518399 — Europe PMC (en), https://europepmc.org/article/MED/42518399 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d84bd2a2adf7 (Metraipolis archive dc_d84bd2a2adf7, sha256 f890f11f1e7c9802c21db2e503ecd1431be0c608dc9b38ff4963368c493c6f06)
BibTeX
@misc{dcd84bd2a2adf7,
  title = {Repurposing Masitinib Mesylate as a Novel FOXM1 Inhibitor for the Treatment of Aggressive Solid Tumors: Preclinical Validation in Human Breast and Oral Cancer… — Europe PMC PMID:42518399},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42518399},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d84bd2a2adf7; sha256 f890f11f1e7c9802c21db2e503ecd1431be0c608dc9b38ff4963368c493c6f06},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42518399. Agents can read the archived copy with the MCP tool read_document.